^
    Apply
    A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations (NCT05503797)
    Phase 2
    Fore Biotherapeutics
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    02/21/2023
    Primary completion :
    06/27/2025
    Completion :
    08/28/2026
    BRAF
    |
    BRAF V600E • BRAF V600
    |
    plixorafenib (FORE-8394) • Tybost (cobicistat)
    Feasibility of CSF and Plasma ctDNA in BRAF-altered Glioma During Treatment With Plixorafenib (NCT06610682)
    Phase 1
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Active, not recruiting
    Last update posted :
    01/13/2025
    Initiation :
    01/10/2025
    Primary completion :
    12/31/2026
    Completion :
    05/15/2027
    BRAF
    |
    plixorafenib (FORE-8394) • Tybost (cobicistat)
    A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors (NCT02428712)
    Phase 1/2
    Fore Biotherapeutics
    Active, not recruiting
    Last update posted :
    04/09/2024
    Initiation :
    04/01/2015
    Primary completion :
    05/01/2024
    Completion :
    12/01/2024
    BRAF
    |
    BRAF mutation
    |
    plixorafenib (FORE-8394)